The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

On all CAR-T products, the FDA is calling for a new boxed warning.

2.

A study has developed molecular markers that predict meningioma recurrence.

3.

Brexpiprazole Safe, Effective in Early-Episode Schizophrenia

4.

AI can identify women at risk of breast cancer years in advance: Study

5.

Advances in TNBC; Mixed News in Lung Cancer Report; Pancreatic Cancer Overdiagnosis?


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot